Xian Jianzhong, Pei Xiaofeng, Lu Wuzhu, Zhong Haihong, Lin Yuhong, Jin Hongjun, Su Zhongzhen
Department of Ultrasound, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Ann Transl Med. 2021 Feb;9(4):336. doi: 10.21037/atm-20-7944.
To summarise the ultrasound manifestations of coronavirus disease-19 (COVID-19) patients with lung lesions and explore the clinical value of bedside ultrasound in the identification of patients at risk of progression to severe disease.
This retrospective study enrolled 31 patients with COVID-19 who were admitted to our hospital from January 18 to February 5, 2020. Lung ultrasounds were performed in all cases to evaluate the ultrasound manifestations of the patient's lung lesions and to determine the lung ultrasound scores (LUS). The Cox proportional hazards regression model was used for the multifactor analysis of 7 candidate parameters, including the LUS and the oxygenation index (PaO/FiO). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of the LUS.
Lung ultrasound images of COVID-19 patients mainly reflected the presence of interstitial pulmonary lesions (90.3%, 28/31). The lung lesions were primarily distributed in the subpleural and peripheral pulmonary zones. Multivariate analyses identified the oxygenation index, the LUS, and the lymphocyte count as factors related to the progression to severe-critical disease in COVID-19 patients (P<0.05). With a cut-off value of 9.5, the area under the ROC curve was 0.910. The LUS showed a sensitivity and specificity of 81.3% and 93.0%, respectively (P≤0.001), with an overall accuracy of 75%.
The lung ultrasound findings in COVID-19 patients were mainly and specifically manifested as interstitial lesions involving the peripheral zones of the lung. In addition, ultrasound imaging could predict the likelihood of COVID-19 patients progressing to severe disease, thereby allowing for early intervention. Thus, lung ultrasounds have great clinical value in monitoring and evaluating COVID-19 patients.
总结新型冠状病毒肺炎(COVID-19)肺部病变患者的超声表现,探讨床旁超声在识别有进展为重症疾病风险患者中的临床价值。
本回顾性研究纳入了2020年1月18日至2月5日期间我院收治的31例COVID-19患者。所有患者均行肺部超声检查,以评估肺部病变的超声表现并确定肺部超声评分(LUS)。采用Cox比例风险回归模型对包括LUS和氧合指数(PaO₂/FiO₂)在内的7个候选参数进行多因素分析。绘制受试者工作特征(ROC)曲线分析以评估LUS的预测价值。
COVID-19患者的肺部超声图像主要反映间质性肺病变的存在(90.3%,28/31)。肺部病变主要分布于胸膜下和肺外周区域。多因素分析确定氧合指数、LUS和淋巴细胞计数为与COVID-19患者进展为危重症相关的因素(P<0.05)。截断值为9.5时,ROC曲线下面积为0.910。LUS的敏感性和特异性分别为81.3%和93.0%(P≤0.001),总体准确率为75%。
COVID-19患者的肺部超声表现主要且特异性地表现为累及肺外周区域的间质性病变。此外,超声成像可预测COVID-19患者进展为重症疾病的可能性,从而实现早期干预。因此,肺部超声在监测和评估COVID-19患者方面具有重要的临床价值。